92 related articles for article (PubMed ID: 9178772)
1. Increased transcription of the E mu-myc transgene and mRNA stabilisation produce only a modest elevation in Myc protein.
Colley SM; Tilbrook PA; Klinken SP
Oncogene; 1997 Jun; 14(22):2735-9. PubMed ID: 9178772
[TBL] [Abstract][Full Text] [Related]
2. The transgenic window on lymphoid malignancy.
Adams JM; Harris AW; Vaux DL; Alexander WS; Rosenbaum H; Klinken SP; Strasser A; Bath ML; McNeall J; Cory S
Princess Takamatsu Symp; 1989; 20():297-309. PubMed ID: 2518688
[TBL] [Abstract][Full Text] [Related]
3. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.
Möröy T; Verbeek S; Ma A; Achacoso P; Berns A; Alt F
Oncogene; 1991 Nov; 6(11):1941-8. PubMed ID: 1658705
[TBL] [Abstract][Full Text] [Related]
4. H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines.
Roland J; Morello D
Cell Growth Differ; 1993 Nov; 4(11):891-900. PubMed ID: 8297795
[TBL] [Abstract][Full Text] [Related]
5. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
6. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
7. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.
Zörnig M; Busch G; Beneke R; Gulbins E; Lang F; Ma A; Korsmeyer S; Möröy T
Oncogene; 1995 Nov; 11(10):2165-74. PubMed ID: 7478538
[TBL] [Abstract][Full Text] [Related]
8. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV.
Zörnig M; Grzeschiczek A; Kowalski MB; Hartmann KU; Möröy T
Oncogene; 1995 Jun; 10(12):2397-401. PubMed ID: 7784089
[TBL] [Abstract][Full Text] [Related]
9. Growth of E mu-myc transgenic B-lymphoid cells in vitro and their evolution toward autonomy.
Langdon WY; Harris AW; Cory S
Oncogene Res; 1988; 3(3):271-9. PubMed ID: 3144697
[TBL] [Abstract][Full Text] [Related]
10. Transformation of bone marrow cells from E mu-myc transgenic mice by Abelson murine leukemia virus and Harvey murine sarcoma virus.
Dyall-Smith D; Cory S
Oncogene Res; 1988 May; 2(4):403-9. PubMed ID: 2840624
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of B-lymphoid tumors in E mu-myc transgenic mice.
Prasad VS; Temple MJ; Davisson MT; Akeson EC; Sidman CL
Cytometry; 1996 Feb; 23(2):131-9. PubMed ID: 8742172
[TBL] [Abstract][Full Text] [Related]
12. Acceleration of B-lymphoid tumorigenesis in E mu-myc transgenic mice by v-H-ras and v-raf but not v-abl.
Langdon WY; Harris AW; Cory S
Oncogene Res; 1989; 4(4):253-8. PubMed ID: 2549487
[TBL] [Abstract][Full Text] [Related]
13. Overexpressed max is not oncogenic and attenuates myc-induced lymphoproliferation and lymphomagenesis in transgenic mice.
Lindeman GJ; Harris AW; Bath ML; Eisenman RN; Adams JM
Oncogene; 1995 Mar; 10(5):1013-7. PubMed ID: 7898919
[TBL] [Abstract][Full Text] [Related]
14. Altered steady-state levels of the messenger RNAs for c-myc and p53 in L1210 cell lines resistant to deoxyadenosine.
Cory JG; Cory AH; Long SD; Carter GL; Johnson CE
Cancer Res; 1992 Apr; 52(7):2000-3. PubMed ID: 1551129
[TBL] [Abstract][Full Text] [Related]
15. The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.
Cotta CV; Leventaki V; Atsaves V; Vidaki A; Schlette E; Jones D; Medeiros LJ; Rassidakis GZ
Cancer; 2008 Feb; 112(3):552-61. PubMed ID: 18085637
[TBL] [Abstract][Full Text] [Related]
16. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M
Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044
[TBL] [Abstract][Full Text] [Related]
17. Lymphomagenesis in E mu-myc transgenic mice can involve ras mutations.
Alexander WS; Bernard O; Cory S; Adams JM
Oncogene; 1989 May; 4(5):575-81. PubMed ID: 2657573
[TBL] [Abstract][Full Text] [Related]
18. Multiple mechanisms of tumorigenesis in E mu-myc transgenic mice.
Sidman CL; Denial TM; Marshall JD; Roths JB
Cancer Res; 1993 Apr; 53(7):1665-9. PubMed ID: 8453639
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligodeoxynucleoside methylphosphonate inhibition of mouse c-myc p65 protein expression in E mu-c-myc transgenic mice.
Wickstrom E; Bacon TA; Wickstrom EL; Werking CM; Palmiter RD; Brinster RL; Sandgren EP
Nucleic Acids Symp Ser; 1991; (24):151-4. PubMed ID: 1841270
[TBL] [Abstract][Full Text] [Related]
20. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
